Can Airflow Limitation in Chronic Obstructive Pulmonary Disease (COPD) be Reversible by Drugs?

This study has been completed.
Information provided by:
Baqiyatallah Medical Sciences University Identifier:
First received: November 6, 2009
Last updated: NA
Last verified: November 2009
History: No changes posted
Critical combination of various approved drugs in management for patients suffering with COPD.

Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Drug: Macrolid, Theophylline, Inhaler Corticosteroids
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Combination of Approved Drug in COPD

Resource links provided by NLM:

Further study details as provided by Baqiyatallah Medical Sciences University:

Primary Outcome Measures:
  • 15% increasing in forced expiratory volume in 1 second [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Enrollment: 64
Study Start Date: February 2008
Study Completion Date: July 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Macrolid, Theophylline, Corticosteroids
Approved drug in this setting
Drug: Macrolid, Theophylline, Inhaler Corticosteroids
we have no permission to include them in detail because of privacy policy of mentioned journal for publication


Ages Eligible for Study:   22 Years to 86 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • current or past smoker COPD

Exclusion Criteria:

  • history of significant occupational or other environmental exposures or a connective tissue disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01010178

Iran, Islamic Republic of
Research Center of Chemical Injuries, Baqiyatallah Medical Sciences University, Mollasadra St,
Tehran, Iran, Islamic Republic of, 19945-546
Sponsors and Collaborators
Baqiyatallah Medical Sciences University
  More Information

Responsible Party: Corresponding Author: Research Center of Chemical Injuries, Baqiyatallah Medical Sciences University Identifier: NCT01010178     History of Changes
Other Study ID Numbers: BMT-1388-2 
Study First Received: November 6, 2009
Last Updated: November 6, 2009
Health Authority: Iran: Ministry of Health

Keywords provided by Baqiyatallah Medical Sciences University:
symptoms PFT

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Cardiovascular Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Phosphodiesterase Inhibitors
Physiological Effects of Drugs
Purinergic Agents
Purinergic Antagonists
Purinergic P1 Receptor Antagonists
Respiratory System Agents
Therapeutic Uses
Vasodilator Agents processed this record on May 03, 2016